Radicava: payments to doctors
Payments that named Radicava as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.1M
- Providers
- 4,847
- Transactions
- 16,561
- Average per transaction
- $66
The per-transaction average — $66 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 4,847 providers the average total is $224, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Mitsubishi Tanabe Pharma America, Inc. | $1,009,111 | 92.9% |
| Tanabe Pharma America, Inc. | $73,616 | 6.8% |
| Mitsubishi Tanabe Pharma Corporation | $2,475 | 0.2% |
| Mitsubishi Tanabe Pharma Development America, Inc. | $631 | 0.1% |